{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:18:08Z","timestamp":1792149488859,"version":"4.4.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,2,22]]},"DOI":"10.1001\/jama.2022.0799","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T16:00:59Z","timestamp":1645545659000},"page":"727","source":"Crossref","is-referenced-by-count":88,"title":["Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder"],"prefix":"10.1001","volume":"327","author":[{"given":"Sheldon H.","family":"Preskorn","sequence":"first","affiliation":[{"name":"Kansas University School of Medicine-Wichita, Wichita"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Zeller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California-Riverside School of Medicine, Riverside"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Finman","sequence":"additional","affiliation":[{"name":"Jupiter Point Pharma Consulting, LLC, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Kakar","sequence":"additional","affiliation":[{"name":"Segal Trials, Ft Lauderdale, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De Vivo","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank D.","family":"Yocca","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Risinger","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"joi220007r1","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.3390\/ijerph18084368","article-title":"The management of psychomotor agitation associated with schizophrenia or bipolar disorder: a brief review.","volume":"18","author":"Pompili","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"joi220007r2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.annemergmed.2018.06.001","article-title":"The characteristics and prevalence of agitation in an urban county emergency department.","volume":"72","author":"Miner","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"2","key":"joi220007r3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","article-title":"Assessment and management of agitation in psychiatry: expert consensus.","volume":"17","author":"Garriga","year":"2016","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"joi220007r4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12888-018-1673-3","article-title":"Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia.","volume":"18","author":"Roberts","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"2","key":"joi220007r5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5811\/westjem.2015.12.28763","article-title":"Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting.","volume":"17","author":"Zeller","year":"2016","journal-title":"West J Emerg Med"},{"issue":"1","key":"joi220007r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5811\/westjem.2011.9.6865","article-title":"Overview of project BETA: Best Practices in Evaluation and Treatment of Agitation.","volume":"13","author":"Holloman","year":"2012","journal-title":"West J Emerg Med"},{"issue":"1","key":"joi220007r7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5811\/westjem.2011.9.6864","article-title":"Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry project BETA de-escalation workgroup.","volume":"13","author":"Richmond","year":"2012","journal-title":"West J Emerg Med"},{"issue":"6","key":"joi220007r8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0269881118776738","article-title":"Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation.","volume":"32","author":"Patel","year":"2018","journal-title":"J Psychopharmacol"},{"key":"joi220007r9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fpsyt.2018.00054","article-title":"1st International Experts\u2019 Meeting on Agitation: conclusions regarding the current and ideal management paradigm of agitation.","volume":"9","author":"Mart\u00ednez-Raga","year":"2018","journal-title":"Front Psychiatry"},{"issue":"2","key":"joi220007r10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14740338.2021.1865911","article-title":"Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium.","volume":"20","author":"Kim","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"joi220007r11","doi-asserted-by":"publisher","first-page":"e1788","DOI":"10.1097\/MJT.0000000000000319","article-title":"Safety and efficacy of dexmedetomidine as a sedative agent for performing awake intubation: a meta-analysis.","volume":"23","author":"Zhou","year":"2016","journal-title":"Am J Ther"},{"issue":"5","key":"joi220007r14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0924-9338(97)83297-X","article-title":"The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability.","volume":"12","author":"Sheehan","year":"1997","journal-title":"European Psychiatry."},{"key":"joi220007r15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-9-18","article-title":"Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room.","volume":"9","author":"Montoya","year":"2011","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"joi220007r16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1","key":"joi220007r17","first-page":"78","article-title":"Double-blind, placebo-controlled, single ascending dose, study to determine the efficacy, safety, and pharmacokinetics of a BXCL 501 (sublingual dexmedetomidine) in agitation associated with schizophrenia or related disorders (M72).","volume":"44","author":"Preskorn","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"joi220007r18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/archpsyc.61.3.310","article-title":"Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.","volume":"61","author":"Gueorguieva","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"joi220007r19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200565090-00003","article-title":"Pharmacological management of acute agitation.","volume":"65","author":"Battaglia","year":"2005","journal-title":"Drugs"},{"issue":"1","key":"joi220007r20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry project BETA psychopharmacology workgroup.","volume":"13","author":"Wilson","year":"2012","journal-title":"West J Emerg Med"},{"issue":"3","key":"joi220007r21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/13543784.2020.1727884","article-title":"The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.","volume":"29","author":"Ward","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"joi220007r22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.pra.0000398410.21374.7d","article-title":"Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment.","volume":"17","author":"Hankin","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"joi220007r23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eurpsy.2019.01.014","article-title":"The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis.","volume":"57","author":"Bak","year":"2019","journal-title":"Eur Psychiatry"},{"issue":"5","key":"joi220007r24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/emp2.v1.5","article-title":"Improving the management of acutely agitated patients in the emergency department through implementation of project BETA (Best Practices in the Evaluation and Treatment of Agitation).","volume":"1","author":"Roppolo","year":"2020","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"joi220007r12","author":"Yocca"},{"key":"joi220007r13","unstructured":"Adedoyin? A, Preskorn? S, Lathia? CD. Pharmacokinetics of dexmedetomidine after a single sublingual dose of BXCL501 in patients with agitation associated with schizophrenia. Poster presented at: the 23rd Annual Conference of the International Society for Bipolar Disorders (S17); May 13-15, 2021. Accessed May 27, 2021."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2789315\/jama_preskorn_2022_oi_220007_1645543259.76878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T16:01:03Z","timestamp":1645545663000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2789315"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.0799","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}